All News
Filter News
Found 2,468 articles
-
The UK-based nanomedicine biotech, previously known as SomaServe, has closed its Series A with some significant biopharma names attached.
-
ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines
11/13/2023
ViaNautis Bio, a groundbreaking nanomedicine company at the forefront of genetic therapies, is excited to announce the successful completion of its Series A funding round, raising $25 million.
-
Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)
11/11/2023
UCB, a global biopharmaceutical company, will present a post hoc analysis of the EXXELERATE trial examining the efficacy of CIMZIA® and adalimumab in patients with rheumatoid arthritis with high rheumatoid factor levels.
-
UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023
11/10/2023
UCB, a global biopharmaceutical company, announced new long-term data from the BIMZELX® Phase 2b study BE AGILE and its open-label extension.
-
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
11/7/2023
Praxis Precision Medicines, Inc. provided a corporate update and reported financial results for the third quarter 2023.
-
Diaccurate Announces the Appointment of Scott Filosi as CEO and Corporate Name Change to Evexta Bio
11/6/2023
Diaccurate SA, a clinical-stage biotechnology company focused on developing targeted therapeutics in oncology, - announces the appointment of Scott Filosi as Chief Executive Officer (CEO), effective November 6, 2023.
-
The Swiss pharma has set up its challenge to AbbVie’s blockbuster immunosuppressive drug Humira with a label expansion for Cosentyx in hidradenitis suppurativa, a painful long-term skin condition.
-
Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting
11/2/2023
Syndax Pharmaceuticals announced that results from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease, will be featured during the Plenary Scientific Session at the 65th American Society of Hematology Annual Meeting being held December 9-12, 2023, in San Diego, California.
-
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
11/2/2023
Incyte (Nasdaq:INCY) today announced that more than 40 abstracts highlighting data from eight of its hematology and oncology products will be presented at the upcoming 65th American Society of Hematology Annual Meeting 2023 (ASH 2023), held December 9-12, 2023, in San Diego and virtually.
-
UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
11/1/2023
UCB announced that it will be presenting results from across its portfolio in generalized myasthenia gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting and the Myasthenia Gravis Association of America Scientific Session taking place November 1-4, 2023.
-
NAYZILAM® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters
10/31/2023
UCB, a global biopharmaceutical company, announced that Epilepsy & Behavior published a post hoc analysis from the Phase 3 open-label extension study of NAYZILAM.
-
Clario's Precision Motion Opal® technology powers University of Oxford breakthrough in Parkinson's Disease
10/27/2023
Clario today announced that the application of Opal® wearable sensor technology (legacy APDM, Inc.), with advisory from Precision Motion scientists, has helped the University of Oxford researchers develop a new understanding of motor symptom progression in Parkinson's Disease, offering promising implications for neuroscience clinical trials and future treatments.
-
While Merck lost out to Pfizer earlier this year in snapping up Seagen, this week the company closed a deal worth a potential $22 billion with Daiichi Sankyo—further evidence of the industry’s insatiable appetite for ADC technology.
-
Following a delay and an initial rejection, UCB’s IL-17A/IL-17F blocker bimekizumab was approved for moderate-to-severe plaque psoriasis, which will now be marketed with the brand name Bimzelx.
-
The complement inhibitor won the FDA’s approval for the treatment of generalized myasthenia gravis, a rare autoimmune disease. The therapy will be sold under the brand name Zilbrysq.
-
Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models
10/18/2023
Tonix Pharmaceuticals Holding Corp. today announced that a study published in the Journal Nature1 by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital (MGH) in collaboration with biotechnology company, eGenesis, utilized TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) as part of the immune modulating regimen to prevent organ transplant rejection.
-
BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
10/18/2023
UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
-
Muscular Dystrophy Association Celebrates FDA Approval of ZILBRYSQ® zilucoplan for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients
10/18/2023
The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of ZILBRYSQ® zilucoplan for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.
-
UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis
10/17/2023
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that ZILBRYSQ® (zilucoplan) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.
-
UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023
10/13/2023
UCB, a global biopharmaceutical company, announced that it will present six abstracts in hidradenitis suppurativa at the 8th Annual Symposium on Hidradenitis Suppurativa Advances, October 13–15 in Phoenix, Arizona.